INNOVATION: DEVELOPING NEW DRUGS AND NEW DRUG DELIVERY SYSTEMS IN LAWRENCE
| 2014 Q4 | story by LIZ WESLANDER    | photos by STEVEN HERTZOG |
Tech

Deciphera lab

Hidden in plain sight among unassuming buildings in downtown and north Lawrence are two high-tech biotechnology companies that are working on innovative cancer treatments that could be available on the market in the future.

CritiTech, a Lawrence born-and-bred drug development company, operates both its labs and business offices in a space along E. 1450 Rd just north of downtown. Deciphera, with its business headquarters in Boston, Mass. has biology and chemistry labs located on the 600 block of Massachusetts Street- right across from the Free State Brewery.

Daniel Flynn, the CSO and Founder of Deciphera Pharmaceuticals, received his Ph.D. in medicinal chemistry at the University of Kansas. Flynn said that when he established Deciphera in 2003, he could have located the company’s research labs anywhere in the country. He chose Lawrence.

Tech

CritiTech lab equipment

“I wasn’t wooed here, I came voluntarily.” Flynn said. “Even back 10 years ago there was a beginning of a desire from the thought leaders of the city wanting to bring Lawrence forward as a regional biotech hub. I wanted to be a part of that.”

Deciphera’s labs were originally located at KU’s Life Science Research Laboratories, at 1501 Wakarusa. In 2011, they moved to their downtown location.

“It’s surprising that we would have a research lab above Chico’s and the Gap, but we worked with city commission to make them comfortable with being us downtown,” Flynn said. “Lawrence is a wonderful town to work in. At least a third of our hires have been KU graduates or KU-affiliated. We have had no problem tapping into the human resources that have been available here.”

Deciphera specializes in developing cancer-fighting pharmaceuticals that use a technology called kinase inhibitors. Kinases are enzymes that transmit signals within cells to help the cells function. Kinase have “switch” mechanisms that allow the enzymes to “turn on” to perform its function, and “turn off” when not needed. Mutations in a kinase switch can cause a kinase to remain on continually, which can cause a cell to become cancerous. Kinase inhibitors work by targeting the faulty kinase switch, which cuts off the ability of tumor cells to thrive and spread.

“Our approach to cancer is not the standard chemotherapy, which is designed to kill any cell whether it is cancer or not,” Flynn said. “Kinase inhibiters are targeted therapeutics – they go into a cell and target the runaway kinase. The side-effect profile is much more favorable this way.”

Flynn said that Deciphera has spent the past five to six years focusing on researching and developing its specialized kinase inhibitor technology platform to produce drug candidates. It now has five drug candidates at various stages development that utilize the company’s technology. The ultimate goal is to advance these candidates into human clinical trials so that they may ultimately be available on the market to treat cancer patients. Clinical trials measure outcomes and assess the safety and effectiveness of a new drug or combination of drugs. New pharmaceuticals undergo three phases of clinical trials before being approved for marketing. Deciphera currently has three drug candidates in Phase I clinical trials, including one that is being developed in partnership with pharmaceutical giant Eli Lily.

Tech

Dechipera, front row left to right: Cynthia Leary, Anjanette Wilhelm & Daniel Flynn. Back row: Mike Kauffman, Bryan Smith, Linda Martin, Susan McElwain & John Lord

Flynn said that partnering with Eli Lily in the early stages of clinical trials was in Deciphera’s best interest for this particular drug. However, the company plans to conduct Phase I trials for its other drug platforms in its Lawrence labs when possible. It will then seek strategic partnerships with pharmaceutical companies once the drugs have advanced to later phases.

“Our design is to finish Phase I clinical trials in-house,” Flynn said. “It is all about risk and reward. If we have internal phase-one data that looks good, that leads to more favorable partnerships in the future.”

Deciphera recently hired Mike Taylor, a veteran of the bioscience deal-making industry, to serve as its new president and CEO. Taylor communes between Lawrence and Boston offices.

“It’s great to have him on board,” Flynn said. “He brings a good business acumen to the company.”

Deciphera currently has 16 total employees between the Lawrence and Boston offices. Although the company is currently focusing its attention on a few of its drug platforms, Flynn said that Deciphera has no shortage of other drugs with the potential to advance into clinical trials.

“We have a backlog of assets,” Flynn said. “Most companies our size have one or two assets, and they live or die based on those. We have a wealth of riches in our war chest.”

Where Deciphera uses its technology to create new drug formulations to fight cancer, CritiTech specializes in reformulating and improving pharmaceuticals that are already on the market. CritiTech is currently working on a reformulated version of the widely administered chemotherapy drug, Paclitaxel. The reformulated drug, which CritiTech has named Nanotax, performed favorably in a recent Phase I clinical trial focusing on ovarian cancer patients at the KU Medical Center.

CritiTech reformulates existing drugs using proprietary technology that transforms existing drug formulations into very fine particles. The core base of CritiTech’s technology was developed at KU by researcher, Bala Subramaniam, and CritiTech has continued to evolve and expand this technology, according to CritiTech President Matthew McClorey. Reformulating existing drugs into smaller particles can have a number of benefits, including making drugs less toxic, more effective and easier to administer.

Tech

President of CritiTech Matthew McClorey

McClorey said that CritiTech’s reformulation of Paclitaxel into Nanotax is an ideal example of what can be done with CritiTech’s technology. Paclitaxel is currently administered to ovarian cancer patients intravenously using a toxic delivery agent called Cremaphor. By reformulating Paclitaxel into smaller particles using its technology, CritiTech’s reformulated version, Nanotax, can be administered straight into the abdomen using water or saline.

“This is important because the Cremaphor creates significant toxicity for the patients. And because the Paclitaxel is administered into the vein, those toxic effects are systemic,” McClorey said. “The results of Nanotax Phase I trial indicated that it can be delivered at the site of the tumor, in a higher concentration, for a longer period of time, and without the typical side effects and toxicity that is associated with the drug that is currently on the market.”

McClorey said that CritiTech plans to move Nanotax forward in advanced clinical trials, and hopes the drug will be on the market in a few years. He also said that there is a good possibility that Nanotax will be applicable to other cancers including breast, liver and colorectal.

“We think we can improve the lives of ovarian cancer patients with this drug,” McClorey said. “We need to do expanded trials to prove that out, but that is why we are doing what we are doing – to improve the quality of life for these women and hopefully help them to live longer.”

With a solid example of what CritiTech’s technology can do well under way, the company is now starting to offer the technology’s service to other drug companies. Just as CritiTech developed a new and improved version of Paclitaxel, it wants to help other pharmaceutical companies.

“We have started providing this third-party drug development in this past year,” McClorey said. “We have had some contracts coming in from companies that are exploring the use of our technology as applied to the compounds that they are developing. Just like we developed a new and improved version of Paclitaxel, we want to help other pharmaceutical companies develop a new and improved version of their products.”

Share.

57 Comments

  1. Awesome blog! Is your theme custom made or did you download it from somewhere? A design like yours with a few simple adjustements would really make my blog jump out. Please let me know where you got your design. Kudos

  2. Thanks for the article. I have continually noticed that many people are needing to lose weight simply because they wish to appear slim and also attractive. On the other hand, they do not usually realize that there are more benefits so that you can losing weight also. Doctors state that overweight people are afflicted with a variety of diseases that can be perfectely attributed to their own excess weight. Thankfully that people that are overweight as well as suffering from various diseases are able to reduce the severity of their illnesses by losing weight. It’s possible to see a continuous but noticeable improvement with health while even a slight amount of fat reduction is obtained.

  3. Wow that was odd. I just wrote an really long comment but after I clicked submit my comment didn’t show up. Grrrr… well I’m not writing all that over again. Regardless, just wanted to say great blog!

  4. 同じ保険期間中に車両保険のご利用が2回以上となった場合、お客さまの自己負担(免責金額)は10万円となり、車の修理代が60万円の場合では、免責金額を差し引き支払われる保険金は50万円となります。 いったんは生産終了となり、排ガス規制への対応とともにW800 STREET/CAFEの2本立てで復活したW800。 Z1000ベースの948cc並列4気筒エンジンは、排気系の変更でユーロ5に対応するとともにエキサイティングなサウンドとした。復活した250cc4気筒エンジンを引っさげ、遂にその姿を現したカワサキ・ かつて海外放浪中にエトワールという名の10歳以上年下のパリジェンヌと結婚していたが、パティシエに取られてしまい離婚している。

  5. Thanks for giving your ideas listed here. The other factor is that when a problem comes up with a laptop motherboard, persons should not have some risk involving repairing this themselves for if it is not done properly it can lead to irreparable damage to the complete laptop. It’s usually safe just to approach the dealer of your laptop for that repair of its motherboard. They have technicians who definitely have an competence in dealing with pc motherboard problems and can get the right diagnosis and execute repairs.

  6. The “calvo” password is exclusive in that it is likely one of the few passwords in the game that can be guessed, quite than read out of a datacube (it appears on a poster in Alex’s office).

  7. EF1 injury was famous alongside Mizpah Highway, where fencing and bushes have been downed, a flag pole was bent, and a few additional industrial buildings had injury to their exteriors, with steel siding and insulation scattered throughout fields.

  8. From the primary of August onwards, avenue distributors begin selling brooches and pins with the National Flag.Our range of Independence Day jewellery designs is aesthetics and graceful.our latest design of Necklace set have numerous classes on the occasion of Independence Day.

  9. From hotel booking to airline reservation, from worldwide business conferences to local schooling roadshows, from an exhibition of recent products to streamlining execution of coaching packages, from maximising the coverage of what you are promoting, Tamarind International has the whole lot for you.

  10. Six people were killed when the roof was lifted off the constructing, and the west-going through partitions of the construction collapsed inward, causing a progressive structural failure that resulted in whole destruction of most of the warehouse.

  11. On the pragmatic side, small-scale fedi would benefit massively from the type of coaching and knowledge about these operations that massive business platforms possess, so if I had been a fedi admin who felt nice about working with Meta, those are the kinds of requests I would be making of my in all probability fairly nice new buddies in horrible places.

  12. The WhatsApp privacy policy update is a basic bait-and-switch: WhatsApp lured users in with a sleek interface and the impression of privateness, domesticated them to take away their autonomy to migrate, and then backtracked on its previous commitment to privacy with minimal consequence.

  13. 藤田さつき (2020年1月20日). “皇族の「人権」どこまで? 目につく「不自由さ」”.退位後のお立場|平成から令和へ 新時代の幕開け|NHK NEWS WEB 2020年1月2日閲覧。著名な企業人が実名で登場する。株式公開(上場・ “株式会社北洋銀行とのATM相互無料提携について”.女王は、やむを得ない特別の事由があるときは、本人の意思にかかわらず、皇室会議の判断で、皇族の身分を離れる(皇室典範11条2項)。

Leave A Reply

Contact to Listing Owner

Captcha Code